Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that it had received approval from an independent review board for its planned human pilot study #3. The approval signals that the company can begin the study, which aims to investigate the first ever DehydraTECH-processed version of tirzepatide, a dual action glucagon-like peptide (“GLP-1”) + glucose-dependent insulinotropic peptide (“GIP”), in an oral dose format. Tirzepatide is approved for use in the U.S. under the Eli Lilly(TM)-owned Zepbound(R) and Mounjaro(R) brands.

Lexaria plans to begin subject enrollment shortly, with the company expecting to make an announcement as soon as the first dosing has started, potentially in late October. The company anticipates the final doses will be administered in late November.

To view the full press release, visit https://cnw.fm/dsWB5

About Lexaria Bioscience Corp.

DehydraTECH(TM) is Lexaria’s patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

NY Cannabis Insider Completes Successful NY Conference

The NY Cannabis Insider conference was hosted at the Crowne Plaza, The Desmond Hotel, in Albany, New York, on September 25, 2024. The state’s premier cannabis event saw a great turnout of over 100 enthusiasts, entrepreneurs, marketers, traders, attorneys, and consultants, from throughout the cannabis industry.

The entry ticket covered all access to the all-day conference, happy hour and lunch, entry to the vendor fair, and offered wonderful opportunity to connect directly with leaders in the cannabis industry. Select vendors arranged for complimentary consultation sessions for attendees.

With evolutions imminent in the cannabis industry, the NY Cannabis Conference provided a powerful forum where thought leaders, giant investors, cannabis professionals, and traders could gather, interact, and discuss the new regulations, trends, upcoming technologies, and cover several points that will pave the way for the future of the cannabis trade. The conference also saw several new collaborations and alliances impacting different aspects of the cannabis industry.

Sponsors and vendors showcased their ideas and products and made important industry connections. Attendees got a chance to get their queries answered by the experts. 

Some industry topics that were discussed at length include:

  • The state of NY cannabis
  • How nationwide legalization could affect U.S. cannabis cultivation
  • Branding via community
  • Collaborating for success
  • Opportunities for innovation in the medical market
  • Playing devil’s advocate with medical market

The NY Cannabis Insider conference hosted panel discussions throughout the day listening, interacting, and sharing insights from all quarters ranging from current retailers including CAURD and SEE participants to AUCC/AUCP licensees, legacy operators, and more. Industry dignitaries graced the event presiding over the speaker sessions. They shared their wisdom and unique experiences on relevant topics that impact the cannabis industry.

To learn more about the conference, visit https://cnw.fm/rcwDz. For more information, follow NY Cannabis Insider on LinkedIn for important industry news and event announcements.

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Washington State Marijuana Industry Readies for Change as Feds Mull Reclassification

Cannabis industry leaders in Washington State are contemplating the implications of reclassification for researchers and local customers. President Joe Biden disclosed in May that the U.S. Department of Justice (DoJ) was considering a substantial change to the classification of cannabis. The U.S. Drug Enforcement Administration (DEA) currently classifies marijuana as a schedule I substance, classing it with methamphetamine and heroin. This classification suggests that there is little to no medicinal benefit to marijuana.

The Biden administration’s proposal suggests moving marijuana to a less severe schedule 3 status, indicating a lower potential for abuse or addiction.

Dr. Susan Ferguson, director of the University of Washington’s Addictions, Drug and Alcohol Institute, noted that the change cannot come fast enough. Ferguson and her team have faced challenges due to what they view as outdated federal cannabis regulations. Currently, Ferguson’s lab is studying the effects of marijuana on mice to explore nonaddictive treatment options, which could potentially lead to breakthroughs in conditions such as epilepsy. Unfortunately, the quality and quantity of cannabis available for research is quite low due to the federal scheduling of marijuana.

On the other hand, critics highlight the risks of addiction and the increasing prevalence of Marijuana Use Disorder, particularly among teenagers. Ferguson acknowledges these concerns but argues that research is essential for achieving medical advancements.

While many in the industry support relaxed federal restrictions, some worry about the consequences. Marijuana store owners, for instance, could benefit from being able to make tax deductions under more lenient federal rules, but some fear that large corporations will eventually dominate the market, pushing out smaller retailers.

Ryan Kunkel, an early pioneer in Washington’s cannabis retail business, has already seen these challenges firsthand. At the height of his career, Kunkel’s company, Have a Heart, held 22 licenses across six states. Now, he’s exiting the business, having sold many of his stores. Today, he only operates a few locations in the Seattle area. “In due course, marijuana will be offered for sale in grocery stores and other establishments alongside tobacco and alcohol,” said Kunkel.

Despite these concerns, Kunkel believes that reclassifying marijuana at the federal level could lead to lower prices for users.

An unprecedented 43,000 remarks were made in the public comment period about the DEA’s rescheduling proposal. The comment window closed on July 22, 2024, but there is still no definitive timeline for the DEA’s final ruling. An administrative hearing is scheduled for Dec. 2, 2024, which may delay any conclusive action until 2025.

This ongoing rescheduling process isn’t only being awaited by companies in Washington State. Even entities in other jurisdictions, such as Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), are also waiting for the final rule so that they can ascertain how their operations and plans could be impacted.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – CannaCon Midwest to Help Drive Business, Accelerate Growth of Cannabis Industry Throughout the Midwest

CannaCon, a leading conference company, today announced that it will host the CannaCon Midwest Cleveland. Scheduled for October 3-4, 2024, the event will be held at the Huntington Convention Center in Cleveland, Ohio. The highly anticipated two-day event is a must-attend for entrepreneurs, founders, growers, dispensary owners, seed investors, medical professionals, policy experts, government regulators, and seasoned industry players. The event is expected to fulfill every cannabis business need throughout the value chain, from seed investments, cultivation supplies, and breakthrough tech innovations to first-rate legal and business advice, world-class genetics, and the sale of extraction equipment and retail displays.

CannaCon Midwest Cleveland also promises an unparalleled networking experience and world-class educational opportunities from widely acclaimed speakers. Attendees will gain the latest insights on technological and financial trends, strategy, marketing, and branding. The event will also feature a state-of-the-art exhibition floor with plenty of vendors and booths showcasing cutting-edge innovations in cannabis and allied industries. CannaCon Midwest Cleveland is designed to drive business and accelerate the growth of the cannabis industry throughout the Midwest for decades to come, supported by the region’s supportive legislation.

To view the full press release, visit https://cnw.fm/VeZ83

About CannaCon

CannaCon is dedicated to creating and strengthening lifelong partnerships within the emerging cannabis industry. Its mission is to provide a global B2B venue for cannabis businesses, marijuana entrepreneurs, investors, and community partners to showcase industry products, people, innovations, and technology. CannaCon is committed to cultivating business values within the cannabis industry through education and responsible community involvement. Learn more at www.CannaCon.org.

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 Expo: New Jersey’s Largest Consumer Cannabis Convention Ends the Summer Season with 3-Days of Industry ‘Edutainment’; Announces Winners of the First-Ever Legal Statewide Cannabis Cup

The 420 Expo (https://www.420expo.com/) recently concluded its third annual three-day event series with over 14,000 cannabis enthusiasts making their way to the New Jersey Convention and Exposition Center, in Edison, September 13-15, 2024.

Presented by Wakit Grinders (https://wakitgrinders.com), the B.Y.O.C. (bring your own cannabis) public event featured access to a large variety of cannabis-friendly vendors and dispensaries, cultivators, CBD businesses, accessories, and beverages, clothing and apparel, jewelry, art, food trucks, celebrity guests, glass blowers and lots of other brands and products. Guests had the opportunity to attend a variety of seminars and engage with canna-focused nonprofits and advocacy groups, as well as learn more about expungements, cannabis industry employment opportunities, and much more. Attendees were also able to experience a massive outdoor consumption area, music, and numerous curated food trucks.

The event also featured the inaugural 420 Expo Cannabis Cup, produced by High End Events. The 420 Expo Cannabis Cup was the first statewide compliant cannabis competition. Some of the state’s premier cultivators entered their favorite strains and products in six different categories. The judge’s kits were available for a limited time at both HoneyGrove Dispensary and NJ Leaf in Freehold to consumers to purchase and then vote on their favorites. The results were revealed on the main stage at an awards ceremony Saturday.

Your inaugural 420 Expo Cannabis Cup winners are: 

Indica

  • 1st, Full Tilt Frost – Donkey
  • 2nd, Garden Greens – Blueberry Cruffin

Hybrid

  • 1st, Garden Greens – Grape Junky
  • 2nd, Brighterside Farms – Free Mac 

Sativa

  • 1st, Clade 9 – J1 
  • 2nd, Garden Greens Super – Lemon Haze 

Non-Infused Pre-Roll

  • 1st, Hillview Farms – White Truffle 
  • 2nd, Hamilton Farms – Night Charmer

Infused Pre-Roll

  • 1st, Mudd Bros – Melon Bomb x KW #11
  • 2nd, Acreage/Superflux – Red Carpet Runtz 

Vapes

  • 1st, Timeless – Jungle Punch
  • 2nd, MPX – Marmalade Ro

“As a community effort, our vision became a reality through the tireless efforts of the area’s cannabis industry thought-leaders and influencers,” says J. Handy, Director of Three Expo Events and co-creator of the 420 Expo. “Our team appreciates all of the hard work done by the High End Events team of Bobby and Bailey Nuggz of High End Events, along with 420 Expo Cup participating dispensaries NJ Leaf and HoneyGrove. We made lots of new friends over the weekend and we can’t wait to see what the future holds.”   

“Thank you to everyone who came out to enjoy a special weekend filled with music, munchies and Mary Jane,” says Dan Davis, Director of Operations for Three Expo Events and co-creator of the 420 Expo. “The feedback and love from both attendees and exhibitors is overwhelming, to say the least. We’re proud to produce this event for the Jersey market and we will continue to do our part to remove the stigma against marijuana by promoting information and legal products that advance this growing industry.”

Notable guest appearances included stars from “The Sopranos,” Vincent Pastore (“Big Pussy”), Federico Castelluccio (“Furio”) and director and reality tv guest Danny Provenzano at the Bada Bloom booth, as well as Clerks star Brian O’Halloran; former WWE champion and UFC fighter, the “Super King of Bros,” Matt Riddle; and “Real Housewives of Jersey” personality, Frank Catania, Sr. at the Dispensaries of New Jersey booth.

Attendees were also able to take advantage of a full schedule of seminars featuring top educators and speakers from around the country, a slate of entertainment featuring stellar musicians on the main stage, daily “Paint & Puff” and “Craft & Chill” sessions from NJ Garden State of Mind, Anja Dispensary and Meesh’s Goods, silent disco, “Joint Rolling” competitions, stoner karaoke and nightly after parties featuring top DJ’s such as Drewski (Hot97 and “Love & Hip Hop New York”).

The 420 Expo is scheduled to return to New Jersey, September 12-14, 2025.

Brands, products, and services targeting medicinal and recreational cannabis users can inquire early about exhibitor/vendor opportunities and secure coveted placements in front of thousands, by requesting a sales kit at https://420expo.com/exhibit. For additional information visit https://420expo.com.

Follow “420 Expo” on Instagram, X/Twitter and Facebook @the420expos.

Receive Early Alerts For The 420 Expo in 2025 at https://420expo.com

ABOUT 420 EXPO:

420 Expo is the largest consumer-based cannabis event in New Jersey. Presented by Wakit Grinders, the third annual event series took place on September 13-15, 2024, and featured over 100 cannabis-related vendors, food trucks, celebrity appearances, live music, seminars, B.Y.O.C. (bring your own cannabis), interactive and immersive experiences, and more. The 420 Expo, the “Ultimate Smoke Sesh,” will return to New Jersey in 2025, September 12-14.

On-site sales of any sort of marijuana or THC is not permitted. In accordance with New Jersey state and local laws, attendees are able to legally consume their own stash in a dedicated outdoor consumption area.

Cannabis industry brands and services, as well as vendors with appealing and ancillary products can inquire about exhibitor/sponsorship opportunities and placement in front of thousands by requesting a sales kit at sales@3xevents.com.

Follow “420 Expo” on Instagram, X/Twitter, and Facebook @the420expos.

Media Contact: Alvin Woods, alvin@themediamodel.com

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Shows Users of Medical Cannabis Report Short-Term Benefits in Quality of Life

A recent study involving hundreds of individuals using medical cannabis has shown significant and rapid improvements in overall health during the first three months of use, according to research from the Philadelphia College of Osteopathic Medicine (PCOM). The findings, published in the “Cannabis Research Journal,” followed almost 400 adults in Pennsylvania who were new to medical marijuana treatments.

The participants, who were 46 years of age on average, used medical cannabis to address more than 20 health conditions recognized under Pennsylvania’s qualifying medical cannabis program. The most common conditions treated were severe chronic pain and anxiety disorders.

The research revealed that the respondents experienced health improvements in all aspects of their lives, including reduced pain, increased energy levels and enhanced physical, emotional and social functioning.

Lead researcher Dr. Michelle R. Lent noted that more research needs to be done to determine the long-term effects of medicinal cannabis use on health and everyday functioning. Further, she emphasized that the study — one of the most extensive so far — provides valuable insights into how medical marijuana use affects people’s lives.

“Knowing which patients can benefit most from particular therapies is crucial in this era of personalized medicine,” she added.

The respondents noted significant gains in their emotional well-being and capacity to carry out everyday duties, among other areas, after three months. Positive changes were also observed in social interactions and physical constraints.

These gains, according to the study, constituted what the researchers defined as clinically relevant progress. Notably, social functioning improved by 20%, emotional health improved by 15% and reported pain levels decreased by 20%. Compared to older adults, younger participants showed the greatest improvements in terms of their physical and pain-related outcomes.

Lent noted that deciding whether to include medical cannabis as part of a treatment plan can be difficult for both patients and healthcare providers. However, studies such as this one offer evidence in favor of more widespread access to medical marijuana treatments.

The researchers assessed the participants at intervals of three, six, nine and twelve months. While data beyond the three-month mark have yet to be fully analyzed, future studies aim to explore whether these early improvements are sustained over the longer term.

The majority of participants in the study were white and female, which may offer additional insights into the specific populations benefiting from medical-marijuana treatments.

As more of these studies are conducted, it will become clearer that the various medical marijuana products from entities such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) possibly make a significant contribution to improving the well-being and health of those who opt for these products in lieu of, or as additions to, their conventional medications.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Michigan Cannabis Sales Boom as Recreational Sales Begin in Ohio

Last month, Ohio kicked off its recreational cannabis sales, raising questions about how this would impact Michigan’s already thriving industry, which attracts many Ohio customers. Michigan had become a popular destination for Ohio residents seeking cannabis, with many dispensaries conveniently located near the state border in cities such as Morenci and Monroe.

Ohio’s dispensaries sold close to $55 million worth of product in the first month of the state’s legal cannabis sales, which got underway in August.

Despite this, the Michigan Marijuana Regulatory Agency has released new data indicating that the state’s dispensaries have not suffered. In actuality, sales kept rising: recreational marijuana sales at Michigan dispensaries reached $294 million in August, up 3% from July’s $286 million. Sales increased significantly from $271 million even in August of the previous year, indicating a 9% growth overall.

A closer look at sales figures from regions bordering Ohio shows a similar trend of increased sales. In southwest Michigan, recreational sales reached $86 million in August, up from July’s $82 million. Likewise, the southeast and east regions of Michigan saw sales grow from $121 million to $123 million.

These increases indicate that Ohio’s entry into the recreational market has not slowed down Michigan’s cannabis industry, particularly in border regions.

However, not everyone in Michigan is seeing that same trend. Sean Lyden, CEO of Green Labs Provisions, a dispensary located in Luna Pier, which is six miles from Ohio’s border, reported a 15% drop in sales during August compared to the previous month. Despite this decline, Lyden remains cautiously optimistic, believing that the most significant challenges may have already passed.

One factor that still draws Ohio customers to Michigan is the price difference between the two states. In Ohio, the cost of an ounce of marijuana flower is around $250, while in Michigan, the same amount was priced at around $80 in August.

Michigan’s cannabis market, now almost five years old, has experienced a substantial drop in prices due to increased competition and supply. For the time being, Ohio’s higher prices and limited number of dispensaries may continue to encourage Ohio residents to cross state lines to purchase marijuana in Michigan, where competition is fiercer and prices are lower.

However, Lyden anticipates that as Ohio’s market grows and becomes more competitive, the situation may change. To stay ahead of potential market shifts, he is considering expanding his business with additional dispensaries in Michigan and possibly in Ohio. This expansion could help his company become less dependent on Ohio customers visiting the Luna Pier location.

The growing sales in these two states are helping to strengthen the reach of the industry, and enterprises in other jurisdictions, such as Aurora Cannabis Corp. (NASDAQ: ACB) (TSX: ACB), will be hoping that the momentum keeps building in those new markets.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Nebraska Certifies Ballot Measures to Legalize Medical Cannabis

Efforts to legalize medical cannabis in Nebraska have officially been approved for the November election, despite a lawsuit and a statewide review of the validity of collected signatures.

Bob Evnen, the secretary of state, announced on Sept. 14, 2024, that the group Nebraskans for Medical Marijuana had gathered an estimated 90,000 legitimate signatures. The announcement was made precisely one year from receiving the signature initiative’s third effort in 2023, which coincided with the finalization of the November 5 ballot.

Evnen mentioned that the procedure for gathering signatures had sparked questions, which the office of Attorney General Mike Hilgers was looking into. One person so far who participated in obtaining signatures faces felony charges as part of the investigation.

Crista Eggers, statewide campaign manager for the medical marijuana proposal, thanked Hilgers and municipal leaders for maintaining openness throughout the petition process. She expressed gratitude to officials for resolving any differences and maintaining the credibility of the public initiative process.

One of the measures — the Nebraska Medical Marijuana Regulation Act — aims to legalize the possession, production, distribution and sale of marijuana for medical use. It also proposes creating the Nebraska Medical Marijuana Commission, which would be responsible for regulating cannabis in the state. If the legislation passes, the commission would be required to establish guidelines for approving or rejecting applications from marijuana-related businesses by July next year, with the first licenses being issued by October 2025.

The second measure — the Nebraska Medical Marijuana Patient Protection Act — seeks to authorize patients to possess a maximum of five ounces of medical marijuana. This measure would also exempt caregivers from legal consequences for helping patients use marijuana and require written recommendations from healthcare providers. For minors, this recommendation would also need to come from a parent or legal guardian.

State law mandates that initiative petitions have valid signatures from at least 7% of Nebraska’s 86,500 registered voters, with at least 5% of the voters in 38 of the 93 counties in the state. Nearly 90,000 of the 114,000 signatures that the campaign presented in July were validated, surpassing the 5% level that was necessary in 52 counties.

However, the campaign is currently facing a legal challenge filed by John Kuehn, a rancher and veterinarian from Heartwell, who previously served in the state legislature. Kuehn claims that Evnen’s office has not provided access to the petition pages as requested under a public records law. He is seeking an independent review of those signatures and has asked the Lancaster County District Court to stop the measures from going before voters or stop the state from certifying any resultant polls results.

Kuehn’s lawsuit also argues that the campaign did not gather enough legitimate signatures and that the proposed measures represent an unconstitutional transfer of regulatory power from the Legislature. Furthermore, the lawsuit challenges the initiatives, stating that cannabis’ classification as a schedule 1 substance under federal law prevents the measures from being enacted.

Cannabis enterprises such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) may regard some of the arguments in the lawsuit to be far-fetched, given that several states have legalized medical and even recreational marijuana despite its current federal classification.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Nebraska Lawsuit Aims to Void State’s Medical Cannabis Ballot Measures

A former Nebraska senator and past member of the Nebraska Health Board has filed a lawsuit aimed at stopping two state medical marijuana ballot petitions. John Kuehn, a rancher and veterinarian from Heartwell, is challenging the placement of these measures on the Nov. 5 , 2024, ballot.

Kuehn has listed seven key reasons for his challenge, including claims of procedural violations and constitutional issues under federal and state laws. Kuehn’s legal team, led by attorneys Cameron E. Guenzel, Steven E. Guenzel and Andrew La Grone (another former state senator), filed the case in Lancaster County District Court. The lawsuit seeks to prevent Bob Evnen, the secretary of state of Nebraska, from approving the two petitions for the ballot. Further, Kuehn wishes to prevent the state from recognizing the election results even if these measures are approved.

The two measures in question would legalize medical marijuana and outline who would be considered a patient, provider and caregiver. The measures are supported by Nebraskans for Medical Cannabis, with leaders including campaign manager Crista Eggers, State Senator Anna Wishart and former State Senator Adam Morfeld. Kuehn’s lawsuit names these campaign leaders as well as Evnen.

Kuehn claims that there were several issues with the petitions, including delays in accessing the signatures, a lack of valid signatures, duplicate entries and an invalid sponsor statement from Wishart. He also argues that the petitions violate the state’s constitutional single-subject rule, unlawfully delegate power to a proposed Nebraska Medical Marijuana Commission and conflict with federal laws banning cannabis as a Schedule 1 substance. The lawsuit further asserts that most signatures were collected either before the official petition circulation period or after the deadline. Kuehn argues that invalid signatures were unlawfully accepted by the secretary of state’s office. However, the lawsuit doesn’t specify exactly how many signatures may be invalid.

Mike Hilgers, the state’s attorney general, announced a press conference to address alleged falsifications in the petition process, though it is unclear if these remarks relate to the medical marijuana measures.

This is not the first attempt for Nebraska to place medical cannabis on the ballot, as previous efforts in 2020 and 2022 fell short due to similar legal challenges. The current campaign marks the group’s third attempt, and group officials are hopeful that this will be their final push. However, the lawsuit presents significant hurdles that could delay or derail their efforts once again.

The cannabis industry, including established enterprises such as SNDL Inc. (NASDAQ: SNDL), will likely be watching how the legal battle pans out and whether voters will finally cast their ballots on this matter as the year draws to an end.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations

  • Lexaria, a global innovator in drug delivery platforms, announced the appointment of Richard Christopher as its new CEO, replacing Chris Bunka who will serve in his new capacity as Executive Strategic Advisor while remaining Chairman of the Board
  • Lexaria also announced entering a Material Transfer Agreement with an undisclosed pharmaceutical industry partner, leading to speculation of which company has taken this formal step to get closer to Lexaria’s technology
  • The company is focusing on this pharmaceutical industry collaboration and on investigations in cardiometabolic and GLP-1 sectors (alternative diabetes and obesity treatments), a huge sector that particularly needs its unmatched technology
  • The company seems one step closer to exploiting commercial opportunities in the sector, with a goal toward associated commercialization of its patented DehydraTECH technology

Lexaria (NASDAQ: LEXX), a global innovator in drug delivery platforms, has, since 2016, worked on the development of its patented DehydraTECH(TM) technology. It has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. These efforts have earned it 46 patents in the United States, European Union and other countries, with many more pending worldwide (https://cnw.fm/mBfkA).

With the success achieved thus far, Lexaria is looking to pivot and focus on pharmaceutical industry collaboration and operations. To help steer it in the right direction, the company appointed Richard Christopher as its new CEO, effective Aug. 31, 2024. He will replace Chris Bunka, who will serve in his new capacity as Executive Strategic Advisor to the management team. He will continue to support and advise Lexaria and remain chairman of the board of directors.

“I’m delighted that I have been appointed to lead Lexaria,” noted Mr. Christopher. “The company is well positioned for an exciting period of growth centered around the advancement and improvement of drug delivery in the GLP-1 marketplace. We are preparing for an active and collaborative new era for Lexaria in the pharmaceutical industry,” he added (https://cnw.fm/kj2tz).

Mr. Christopher will lend his vast experience spanning more than three decades in the medical device and pharmaceutical industries. He also has domestic and international experience in leadership, operations, acquisitions/licensing, business development, strategic planning, and capital markets. Most recently, he was the Chief Financial Officer at InVivo Therapeutics, a research and clinical-stage biomaterials and biotechnology company focusing on treating spinal cord injuries.

This appointment directly followed the Material Transfer Agreement with a pharmaceutical company (“PharmaCO”) to evaluate Lexaria’s DehydraTECH technology in a pre-clinical setting. Under the terms of the agreement, Lexaria will formulate and supply certain DehydraTECH compositions for use in animal studies. PharmaCo has been awarded a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under examination, and the project should be completed within roughly six months or less (https://cnw.fm/62ydz).

Lexaria is looking to double down on its DehydraTECH research and commercialization. This move points to this commitment and ushers in a new chapter for the company. Its management is optimistic about the future, not just from a commercial standpoint and creating shareholder value, but also by positively transforming human health.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN